Xiidra, in a 5% solution formulation, is indicated for signs and symptoms of dry eye disease in adults, and is the only prescription eye drop approved for this use. The US Food and Drug ...

Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire in 2019, outlining the sales potential in this market niche. But with ...

If underlying inflammation is present, the prescription eye drop XIIDRA® (lifitegrast ophthalmic solution) 5%, used to treat the signs and symptoms of chronic dry eye by targeting inflammation ...

With nearly 210 million individuals affected by dry eye syndrome globally, the demand for effective treatment solutions has surged significantly. The condition is particularly prevalent among aging ...